NVP-BHG712 is an orally active selective inhibitor of EphB4, which plays a significant role in vessel development, vascular development, and tumor angiogenesis. This compound exhibits anticancer chemotherapeutic and anti-angiogenic activity, inhibiting EphB4 autophosphorylation and VEGF-induced angiogenesis.
| Cas No. | 940310-85-0 |
|---|---|
| Purity | ≥98% |
| Formula | C26H20F3N7O |
| Formula Wt. | 503.48 |
| Chemical Name | 4-methyl-3-(1-methyl-6-(pyridin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-ylamino)-N-(3-(trifluoromethyl)phenyl)benzamide - |
| IUPAC Name | 4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide |
| Solubility | DMSO 101 mg/mL |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet | N8460 Info Sheet PDF |
|---|
Wnuk M, Hlushchuk R, Janot M, et al. Podocyte EphB4 signaling helps recovery from glomerular injury. Kidney Int. 2012 Jun;81(12):1212-25. PMID: 22398409.
Martiny-Baron G, Holzer P, Billy E, et al. The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis. Angiogenesis. 2010 Sep;13(3):259-67. PMID: 20803239.
